<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2022-21-4-43-46</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-87</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Состояние когнитивных функций при COVID-19 в остром и восстановительном периодах</article-title><trans-title-group xml:lang="en"><trans-title>Cognitive Functions During Acute Period of COVID-19 and Recovery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9029-4553</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кабыш</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kabysh</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кабыш Сергей Сергеевич — аспирант кафедры нервных болезней с курсом</p><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1 Partizan Zheleznyak St., Krasnoyarsk, 660022; 12 Instrumentalnaya St., Krasnoyarsk, 660123</p></bio><email xlink:type="simple">sergioowl@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9058-8818</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпенкова</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpenkova</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карпенкова Алёна Дмитриевна — ординатор кафедры нервных болезней с курсом</p><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1 Partizan Zheleznyak St., Krasnoyarsk, 660022</p></bio><email xlink:type="simple">pobejdaujay@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4778-2586</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прокопенко</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Prokopenko</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Прокопенко Семён Владимирович — д. м. н., профессор, заведующий кафедрой нервных болезней с курсом; руководитель Центра нейрореабилитации</p><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1 Partizan Zheleznyak St., Krasnoyarsk, 660022; 34B Karl Marks Str., Krasnoyarsk, 660049</p></bio><email xlink:type="simple">s.v.proc.58@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4748-7907</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голикова-Черешкевич</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golikova-Chereshkevich</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голикова-Черешкевич Александра Валериевна — клинический психолог </p><p>660123, г. Красноярск, ул. Инструментальная, д. 12</p></bio><bio xml:lang="en"><p>12 Instrumentalnaya St., Krasnoyarsk, 660123</p></bio><email xlink:type="simple">89658908573@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1489-5058</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наркевич</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Narkevich</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наркевич Артём Николаевич — д. м. н., доцент, заведующий лабораторией медицинской кибернетики и управления в здравоохранении, заведующий кафедрой медицинской кибернетики и информатики, декан медико-психолого-фармацевтического факультета</p><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1 Partizan Zheleznyak St., Krasnoyarsk, 660022</p></bio><email xlink:type="simple">narkevichart@gmail.com</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской Федерации; КГБУЗ «Красноярская межрайонная клиническая больница № 20 имени И. С. Берзона»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Professor V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Federation Ministry of Health; I.S. Berzon Krasnoyarsk Interregional Clinical Hospital No. 20 (a Territorial Government-funded Healthcare Institution)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской Федерации; ФГБУ «Федеральный Сибирский научно-клинически центр» Федерального медико-биологического агентства Российской&#13;
Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Professor V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Federation Ministry of Health</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской Федерации; ФГБУ «Федеральный Сибирский научно-клинический центр» Федерального медико-биологического агентства Российской&#13;
Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Professor V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Federation Ministry of Health; Federal Siberian Scientific and Clinical Centre of the Federal Medical and Biological Agency of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>КГБУЗ «Красноярская межрайонная клиническая больница № 20 имени И. С. Берзона»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.S. Berzon Krasnoyarsk Interregional Clinical Hospital No. 20 (a Territorial Government-funded Healthcare Institution)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Professor V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Federation Ministry of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>15</day><month>02</month><year>2025</year></pub-date><volume>21</volume><issue>4</issue><issue-title>НЕВРОЛОГИЯ. ПСИХИАТРИЯ</issue-title><fpage>43</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кабыш С.С., Карпенкова А.Д., Прокопенко С.В., Голикова-Черешкевич А.В., Наркевич А.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Кабыш С.С., Карпенкова А.Д., Прокопенко С.В., Голикова-Черешкевич А.В., Наркевич А.Н.</copyright-holder><copyright-holder xml:lang="en">Kabysh S.S., Karpenkova A.D., Prokopenko S.V., Golikova-Chereshkevich A.V., Narkevich A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/87">https://docru.elpub.ru/jour/article/view/87</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: установить влияние коронавирусной инфекции, вызванной COVID-19, осложненной пневмонией, на состояние когнитивных функций пациентов.</p></sec><sec><title>Дизайн</title><p>Дизайн: проспективное исследование.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 32 пациента основной группы с коронавирусной инфекцией на 2–3-й койко-день лечения в стационаре, на 8–10-й день, через 2 месяца после госпитализации и 30 клинически здоровых участников контрольной группы. Когнитивные функции оценивали с помощью нейропсихологических тестов: Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), Frontal Assessment Battery (FAB), The Clock-drawing Test (CDT). Скрининг симптомов тревоги и депрессии проводился при помощи шкалы Hospital Anxiety and Depression Scale (HADS).</p></sec><sec><title>Результаты</title><p>Результаты. В основной группе в остром и восстановительном периодах инфекции наблюдались статистически значимые когнитивные нарушения по данным MMSE, MoCA, FAB в отличие от контрольной группы (p &lt; 0,001). На 2–3-й день нахождения в стационаре и 8–10-й день значения MMSE составили 22 [22; 29] и 22 [19,2; 23,7] балла; MoCA — 26 [21; 28] и 21 [18; 23] балл, FAB — 13 [10; 18] и 10 [8; 12] баллов, через 2 месяца после госпитализации MMSE — 29 [26,8; 30] баллов (р = 0,008 для отличия от показателей на 2–3-й и 8–10-й день), MoCA — 25 [22; 27] баллов (р = 0,03 для отличия от значения на 8–10-й день), FAB — 16 [14,5; 17] баллов (р = 0,004 и р = 0,02). Состояние когнитивных функций, измененных в остром периоде заболевания, еще более ухудшалось к 8–10-му дню госпитализации и имело тенденцию к нормализации через 2 месяца. По данным шкалы HADS, отклонений от нормы не было, что говорит об отсутствии тревоги и депрессии у исследуемых пациентов, медиана составила менее 8 баллов. Показатели СDT также не отклонялись от нормы как в остром, так и в восстановительном периодах.</p></sec><sec><title>Заключение</title><p>Заключение. Коронавирусная инфекция влияет на когнитивный статус. При выявлении у больных когнитивной дисфункции могут быть рекомендованы препараты нейропротективного ряда, немедикаментозная когнитивная реабилитация. Вполне вероятным является развитие когнитивных нарушений как самостоятельного синдрома, течение которого не связано напрямую с соматическим выздоровлением.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Study Objective</title><p>Study Objective: To identify the impact from the pneumonia-complicated COVID-19 coronavirus infection over patients’ cognitive functions.</p></sec><sec><title>Study design</title><p>Study design: Perspective study.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. We examined 32 patients with COVID from the study group on days 2–3, 8–10 in inpatient settings, after 2 months of hospitalisation vs 30 healthy controls. Cognitive functions were evaluated using the following neuropsychologic tests: Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), Frontal Assessment Battery (FAB), The Clock-drawing Test (CDT). Signs of anxiety and depression were screened using the Hospital Anxiety and Depression Scale (HADS).</p></sec><sec><title>Study Results</title><p>Study Results. During the acute and recovery periods, patients from the study group demonstrated statistically significant cognitive disorders as per MMSE, MoCA, FAB vs controls (p &lt; 0.001). On days 2–3 and 8–10 in inpatient settings, MMSE was 22 [22; 29] and 22 [19.2; 23.7] points; MoCA — 26 [21; 28] and 21 [18; 23] points, FAB — 13 [10; 18] and 10 [8; 12] points; in 2 months after hospitalisation, MMSE was 29 [26.8; 30] points (р = 0.008 vs days 2–3 and 8–10), MoCA — 25 [22; 27] points (р = 0.03 vs days 8–10), FAB — 16 [14.5; 17] points (р = 0.004 and р = 0.02). The condition of cognitive functions measured during the acute period of the disease worsened even more by days 8–10 of hospitalisation and tended to normalise in 2 months. As per HADS, there were no abnormal findings; therefore, the patients were neither anxious, nor depressed, and the median was 8 points. СDT values were normal as well, both in acute period and during recovery.</p></sec><sec><title>Conclusion</title><p>Conclusion. The coronavirus infection impacts the cognitive status. For cognitive dysfunctions, neuroprotectives and non-drug cognitive rehabilitation can be recommended. Cognitive dysfunctions are quite an expected independent syndrome, the course of which is not directly associated with somatic recovery.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>когнитивные нарушения</kwd><kwd>коронавирусная инфекция</kwd><kwd>пандемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>cognitive disorders</kwd><kwd>coronavirus infection</kwd><kwd>pandemic</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ellul M.A., Benjamin L., Singh B., Lant S. et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767–83. DOI: 10.1016/S1474-4422(20)30221-0</mixed-citation><mixed-citation xml:lang="en">Ellul M.A., Benjamin L., Singh B., Lant S. et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767–83. DOI: 10.1016/S1474-4422(20)30221-0</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Troyer E.A., Kohn J.N., Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 2020; 87: 34–9. DOI: 10.1016/j.bbi.2020.04.027</mixed-citation><mixed-citation xml:lang="en">Troyer E.A., Kohn J.N., Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 2020; 87: 34–9. DOI: 10.1016/j.bbi.2020.04.027</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Song E., Zhang C., Israelow B., Lu-Culligan A. et al. Neuroinvasion of SARSCoV-2 in human and mouse brain. J. Exp. Med. 2021; 218(3): e20202135. DOI: 10.1084/jem.20202135</mixed-citation><mixed-citation xml:lang="en">Song E., Zhang C., Israelow B., Lu-Culligan A. et al. Neuroinvasion of SARSCoV-2 in human and mouse brain. J. Exp. Med. 2021; 218(3): e20202135. DOI: 10.1084/jem.20202135</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020; 92(6): 552–5. DOI: 10.1002/jmv.25728</mixed-citation><mixed-citation xml:lang="en">Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020; 92(6): 552–5. DOI: 10.1002/jmv.25728</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mizurini D.M., Hottz E.D., Bozza P.T., Monteiro R.Q. Fundamentals in COVID-19- associated thrombosis: molecular and cellular aspects. Front. Cardiovasc. Med. 2021; 8: 785738. DOI: 10.3389/fcvm.2021.785738</mixed-citation><mixed-citation xml:lang="en">Mizurini D.M., Hottz E.D., Bozza P.T., Monteiro R.Q. Fundamentals in COVID-19- associated thrombosis: molecular and cellular aspects. Front. Cardiovasc. Med. 2021; 8: 785738. DOI: 10.3389/fcvm.2021.785738</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen R., Wang K., Yu J., Howard D. et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front. Neurol. 2021; 11: 573095. DOI: 10.3389/fneur.2020.573095</mixed-citation><mixed-citation xml:lang="en">Chen R., Wang K., Yu J., Howard D. et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front. Neurol. 2021; 11: 573095. DOI: 10.3389/fneur.2020.573095</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Singh H., Singh A., Khan A.A., Gupta V. Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease. Microb. Pathog. 2021; 158: 105023. DOI: 10.1016/j.micpath.2021.105023</mixed-citation><mixed-citation xml:lang="en">Singh H., Singh A., Khan A.A., Gupta V. Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease. Microb. Pathog. 2021; 158: 105023. DOI: 10.1016/j.micpath.2021.105023</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мартынов М.Ю., Боголепова А.Н., Ясаманова А.Н. Эндотелиальная дисфункция при COVID-19 и когнитивные нарушения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021; 121(6): 93–9. DOI: 10.17116/jnevro202112106193</mixed-citation><mixed-citation xml:lang="en">Martynov M.Yu., Bogolepova A.N., Yasamanova A.N. Endothelial dysfunction in COVID- 19 and cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021; 121(6): 93–9. (in Russian). DOI: 10.17116/jnevro202112106193</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nzou G., Wicks R.T., VanOstrand N.R., Mekky G.A. et al. Multicellular 3D neurovascular unit model for assessing hypoxia and neuroinflammation induced blood-brain barrier dysfunction. Sci. Rep. 2020; 10(1): 9766. DOI: 10.1038/s41598-020-66487-8</mixed-citation><mixed-citation xml:lang="en">Nzou G., Wicks R.T., VanOstrand N.R., Mekky G.A. et al. Multicellular 3D neurovascular unit model for assessing hypoxia and neuroinflammation induced blood-brain barrier dysfunction. Sci. Rep. 2020; 10(1): 9766. DOI: 10.1038/s41598-020-66487-8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gheblawi M., Wang K., Viveiros A., Nguyen Q. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 2020; 126(10): 1456–74. DOI: 10.1161/CIRCRESAHA.120.317015</mixed-citation><mixed-citation xml:lang="en">Gheblawi M., Wang K., Viveiros A., Nguyen Q. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 2020; 126(10): 1456–74. DOI: 10.1161/CIRCRESAHA.120.317015</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">De Lorenzo R., Conte C., Lanzani C., Benedetti F. et al. Residual clinical damage after COVID-19: a retrospective and prospective observational cohort study. PLoS One. 2020; 15(10): e0239570. DOI: 10.1371/journal.pone.0239570</mixed-citation><mixed-citation xml:lang="en">De Lorenzo R., Conte C., Lanzani C., Benedetti F. et al. Residual clinical damage after COVID-19: a retrospective and prospective observational cohort study. PLoS One. 2020; 15(10): e0239570. DOI: 10.1371/journal.pone.0239570</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Дьякова Е.В., Спиридонова Н.С., Мингазова Л.И., Низамова С.Р. и др. Когнитивные нарушения у пациентов, перенесших COVID-19. Практическая медицина. 2021; 19(4): 99–103. DOI: 10.32000/2072-1757-2021-4-99-103</mixed-citation><mixed-citation xml:lang="en">Dyakova E.V., Spiridonova N.S., Mingazova L.I., Nizamova S.R. et al. Cognitive impairments in patients after COVID-19. Practical Medicine. 2021; 19(4): 99–103. (in Russian). DOI: 10.32000/2072-1757-2021-4-99-103</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
